Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
| Brand name | CINACALCET |
| Generic name | CINACALCET |
| Active ingredient(s) | CINACALCET HYDROCHLORIDE |
| Distributed by / for | Accord Healthcare, Inc., Durham, NC 27703 |
| NDC | 16729-441-10 |
| Full product label | Cinacalcet Tablets, 60 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-441-10, b) 90 Tablets per bottle, NDC: 16729-441-15, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad - 382 210, INDIA. |
| Recalling firm | ACCORD HEALTHCARE, INC. |
| Distribution | Nationwide in the USA and PR |
| Quantity | N/A |
| Recall initiated | 2024-10-10 |
| Report date | 2024-11-06 |
| Recall completed | — |
| Recall number | D-0031-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Raleigh NC United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗